The companies will work with investigators to share the results with the scientific community
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
This advanced technology is specifically tailored for individuals with high power prescriptions, aiming to free the 18-35 age group from the reliance on eyeglasses
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
The survey findings for Delhi-NCR revealed that speech sound disorders exhibit higher prevalence rates in the 6-12 years age group
Take proper precautions and seek timely treatment!
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
Subscribe To Our Newsletter & Stay Updated
